Catalysts and Cascades: Combatting PNH With Complement Inhibitors

Released On
August 1, 2022

Expires On
August 1, 2023

Media Type
Internet

Completion Time
60 minutes

Specialty
Hematology-Oncology

Topic(s)
Bleeding Disorders, Oncology

Scroll to the Bottom of this Information to Begin this Course

Provided by Integrity Continuing Education, Inc.

Supported in whole by an educational grant from Apellis Pharmaceuticals, Inc.

Credit Available

  • Physicians — maximum of 1.0 AMA PRA Category 1 Credit

All other healthcare professionals completing this course will be issued a statement of participation.

Target Audience

This educational program is designed for hematologists, oncologists, and other healthcare providers involved in managing care for patients with paroxysmal nocturnal hemoglobinuria (PNH), including primary care physicians, physician assistants, and nurse practitioners.

Program Overview

PNH is a rare immunologic disorder that leads to the destruction of red blood cells through the complement cascade. Recently, two complement inhibitors (a long-acting C5 inhibitor and antagonist of C3) were approved by the FDA to treat PNH. Several other agents are also in phase 3 development. With these disease-modifying drugs, patients with PNH can now expect to live a relatively normal lifespan, but only if physicians and other members of the healthcare team know how to recognize and diagnose this disease and are familiar with its treatment options.

Join expert Dr. Carlos de Castro as he walks through the pathophysiology of PNH, explores the mechanism of action (MOA) of these new agents and their role in treatment, and discusses individualized therapeutic approaches. This video-based activity is complemented with a slide presentation, followed by a puzzle-based game.

Challenge yourself though a series of assessments on the complement cascade pathways, key clinical trial information, and safety and side effect profiles of newer therapies to complete the puzzle. The puzzle will reveal the MOA of complement inhibitors recently approved to treat PNH.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Explain how the pathophysiology of PNH affects management
  • Evaluate the MOAs of new agents and their place in treatment
  • Identify patients who are candidates for new PNH therapies 

Faculty

FACULTY_NAME


Carlos M. de Castro III, MD
Professor of Medicine
Department of Medicine
Duke University
Durham, North Carolina

Physician Accreditation Statement

Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.


Physician Credit Designation

Integrity Continuing Education, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosures of Conflicts of Interest

Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME activity:

Carlos M. de Castro III, MD
  • Consultant: Alexion Pharmaceuticals, Apellis, Biocryst
  • Data Safety Monitoring Board: Regeneron
  • Researcher: Apellis
  • Speaker: Apellis
  • Steering Committee: Novartis

The Integrity Continuing Education, Inc. planners and managers have nothing to disclose.

Instructions for Participation and Credit

There are no fees for participating and receiving CME credit for this activity. During the period of August 1, 2022 through August 1, 2023 participants must:

  1. Read the learning objectives and faculty disclosures
  2. Complete the pretest
  3. Study the educational activity
  4. Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Contact Information

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or cme@integrityce.com